Wechselwirkungen · Prezista
PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 66–67
HOS-116535 · Präparat HOS-094447
66 UROLOGICAL DRUGS Fesoterodine Not studied. Use with caution. Monitor for Solifenacin fesoterodine or solifenacin adverse reactions, dose reduction of fesoterodine or solifenacin may be necessary. # Studies have been performed at lower than recommended doses of darunavir or with a different dosing regimen (see section 4.2 Posology). † The efficacy and safety of the use of PREZISTA with 100 mg ritonavir and any other HIV PI (e.g. (fos)amprenavir and tipranavir) has not been established in HIV patients. According to current treatment guidelines, dual therapy with protease inhibitors is generally not recommended. ‡ Study was conducted with tenofovir disoproxil fumarate 300 mg once daily.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): solifenacin (HOS-116433) protease (HOS-085623) amprenavir (HOS-086183) fesoterodine (HOS-116432) tenofovir disoproxil fumarate (HOS-110471) ritonavir (HOS-084521) tipranavir (HOS-086184)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 4a138fc9e1c788e1d7747ba233c9254854c8390d924be8b5ea4eacff3a14e676 · Zeichen 69769–70897 im Abschnitt